a man in a suit

Mayank Mamtani

Managing Director & Group Head of Healthcare

Sectors

  • Biotech
  • Service & Technology
  • Specialty & Biopharma
  • Specialty Pharmaceuticals

Research Coverage

  • Actinium Pharmaceuticals, Inc. (ATNM)
  • Agenus, Inc. (AGEN)
  • Altimmune, Inc. (ALT)
  • Arrowhead Pharmaceuticals, Inc. (ARWR)
  • Azenta, Inc. (AZTA)
  • BioLife Solutions, Inc. (BLFS)
  • BioVie, Inc. (BIVI)
  • Cassava Sciences, Inc. (SAVA)
  • Checkpoint Therapeutics, Inc. (CKPT)
  • Cognition Therapeutics, Inc. (CGTX)
  • Cryoport, Inc. (CYRX)
  • CymaBay Therapeutics, Inc. (CBAY)
  • Fortress Biotech, Inc. (FBIO)
  • Fusion Pharmaceuticals, Inc. (FUSN)
  • Harrow Health, Inc. (HROW)
  • Intercept Pharmaceuticals, Inc. (ICPT)
  • IVERIC bio, Inc. (ISEE)
  • Lantheus Holdings, Inc. (LNTH)
  • Lineage Cell Therapeutics, Inc. (LCTX)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • MediciNova, Inc. (MNOV)
  • Mustang Bio, Inc. (MBIO)
  • NGM Biopharmaceuticals, Inc. (NGM)
  • NightHawk Biosciences, Inc. (NHWK)
  • Novavax, Inc. (NVAX)
  • Spectrum Pharmaceuticals, Inc. (SPPI)
  • TG Therapeutics, Inc. (TGTX)
  • Tiziana Life Sciences Plc (TLSA)
  • Vaxart, Inc. (VXRT)
  • X4 Pharmaceuticals, Inc. (XFOR)

Biography

Mayank Mamtani is managing director, group head of healthcare equity research with B. Riley Securities leading a team of 10+ research professionals focused on delivering investment recommendations to institutional clients within key industry sub-verticals - therapeutics/vaccines, medical devices, digital health and diagnostics. He also serves in the senior biotechnology research analyst capacity leading coverage of over 25 SMiD cap names, leveraging 15+ years of relevant industry and academic experience, primarily focused on cutting-edge therapeutics' innovation in hematology-oncology, infectious diseases, liver diseases, neuroscience, and ophthalmology.

Mayank has been one of the leading voices on the Street in prophylactic innovations for cardiovascular and infectious diseases, both aimed at reducing significant burden on global healthcare systems. Individually, was ranked within 1% among thousands of qualifying Analysts by TipRanks. Mayank's research and opinions are widely referenced, with appearances in the Associated Press, Bloomberg, CNBC, Forbes, the Wall Street Journal, and various industry specific trade publications, e.g., MedCity, Science Magazine.

Prior to B. Riley, he served in roles of increasing responsibility at Amgen, SVB Securities (formerly known as Leerink Partners) and Deallus Consulting.

Mayank is FINRA certified with Series 7, 24, 63, 86 and 87 licenses. He holds an M.Sc. in biotechnology management from Carnegie Mellon University and a B.E. in biotechnology from Delhi College of Engineering.

B. Riley Securities provides a full suite of investment banking, corporate finance, advisory, research, and sales and trading services. Investment banking services include initial, secondary and follow-on offerings, institutional private placements, merger and acquisition (M&A) advisory, SPACs, corporate restructuring and recapitalization. B. Riley is nationally recognized and highly ranked for its proprietary small-cap equity research. B. Riley Securities formerly operated as B. Riley FBR following the merger of B. Riley & Co. and FBR & Co.